The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration
Recruiting
N/A
Interventional Study
Frontotemporal Lobar Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 50 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 80 (estimated)
- Sponsor
- Nantes University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and/or language. From a pathological standpoint, like the great majority of neurodegenerative disorders, FTLD are proteinopathies, which are characterized by the presence of specific protein deposits in the Central Nervous System (CNS). Accordingly, the two main deposi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria (patients):
* Adressed or followed at memory clinic or ALS expert center at Nantes university hospital.
* Aged 50-75 years
* Fulfilling current diagnosis criteria for one of the disorder: vcfFTD, non-Alzheimer PPA (semantic or non fluent), DCB or PSP,ALS
* MMSE ≥ 18
* Membership …
Contacts